| By Alex Shaw, Pharmaceutical Manufacturing News |
| Friday, 19 June 2009 |
 |
Zhejiang Huahai Pharmaceutical Co., Ltd, one of the leading modern large-scale pharmaceutical enterprises in China that specializes in the research and development, manufacture and marketing of APIs,
|
|
intermediates and preparations, recorded an impressive growth of 14 percent in revenues in the first quarter of 2009, while many other peers saw negative business growth during the period amid the economic downturn. Huahai Pharmaceutical’s new preparation research and development center under construction
is expected to be completed at the end of this year, while its R&D center for APIs has already been put into operation.
In addition, the pharmaceutical maker plans to invest approximately RMB 200 million (approx. US$29 million) to build a sartan drug production facility with an annual capacity of 170 tons this year, making it number one worldwide in terms of sartan drug production. |
|
|
Sartan drugs to be manufactured by the facility will be all exported to Europe and America.
Chen Baohua, Chairman of Huahai Pharmaceutical, said that the pharmaceutical producer will invest nearly RMB500 million (approx. US$73.5 million) to create a preparations facility with an annual capacity of 10 billion tablets in 2011, making it the largest preparation manufacturer not only in China but also worldwide.
The establishment of the facility will lay a sound foundation for Huahai Pharmaceutical’s cooperation with a number of large producers of APIs and generic drugs while strengthening its capacity in independent research and development.
The existing preparations production line of the company is not only the first one in China to completely use imported equipment but also the sole one to receive the certification from the US Food and Drug Administration, according to Xu Pijie, manager of Preparation Production and Technology at Huahai |
|
Pharmaceutical. Given its new large preparation facility to be built in 2011, the drug maker’s preparation capacity is expected to exceed its API capacity over the next three to five years.
With Chen at the helm, the drug producer has successfully speeded up the transformation of its product mix, with a new emphasis on both APIs and preparations rather than the combination of intermediates and APIs, despite the worsening international economic conditions.
Chen added that the financial crisis, in fact, is not totally bad for Huahai Pharmaceutical as it has provided a great opportunity for the company to optimize its corporate structure.
Want to read more?
China’s domestic paracetamol manufacturers engage in price war
Chemical API exports from China tumble in first two months
China’s exports of preparations for western medicines exceed US$1 billion in 2008
|
|
|
